According to a new study published by the European Journal of Pharmacology, and epublished by the U.S. National Institute of Health, cannabidiol (CBD) reduces airway inflammation and fibrosis in experimental allergic asthma.
“Asthma remains a major public health problem and, at present, there are no effective interventions capable of reversing airway remodelling”, states the study’s abstract. “Cannabidiol (CBD) is known to exert immunomodulatory effects through the activation of cannabinoid-1 and -2 (CB1 and CB2) receptors located in the central nervous system and immune cells, respectively.” However, “as the role of CBD on airway remodelling and the mechanisms of CB1 and CB2 aren’t fully elucidated, this study was designed to evaluate the effects of cannabidiol in this scenario”
For the study. allergic asthma was induced in mice. “CBD treatment, regardless of dosage, decreased airway hyperresponsiveness, whereas static lung elastance only reduced with high dose.” These outcomes “were accompanied by decreases in collagen fibre content in both airway and alveolar septa and the expression of markers associated with inflammation in the bronchoalveolar lavage fluid and lung homogenate.”